Showing 381-390 of 792 results for "".
- Ultherapy Decolletage Treatment Now FDA Clearedhttps://practicaldermatology.com/news/20140707-ultherapy_dcolletage_treatment_now_fda_cleared/2459179/The FDA cleared Ulthera, Inc.'s Ulthera System for the non-invasive treatment of the chest to improve lines and wrinkles of the décolleté. The Ultherapy Décolletage Treatment uses the system's signature imaging and micro-focued ultr
- Congress Establishes New Caucus on Skin Cancerhttps://practicaldermatology.com/news/20130708-congress_establishes_new_caucus_on_skin_cancer/2459502/A new bipartisan Congressional Member Organization will address the growing epidemic of skin cancer among Americans. Led by representatives Jim Cooper (D-TN-5th), Carolyn Maloney (D-NY-12th), Peter Roskam (R-IL-6th), and Charlie Dent (R-PA-15th), the caucus will support legislative activities and pr
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Bill Collection Made Tougher by Recent Changes in Credit Reportinghttps://practicaldermatology.com/news/Bill-Collection-Made-Tougher-Recent-Changes-Credit-Reporting/2471259/Americans owe $220 billion in medical debt,1 and the most effective method for collecting money could soon cease to be an option. Mark Nestor, MD, PhD, highlighted this issue during a presentation at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “Ba
- Dr. Lebwohl: Don't Delay GPP Treatment for TB Testing or Skin Biopsyhttps://practicaldermatology.com/news/Dr-Lebwohl-Dont-Delay-GPP-Treatment-TB-Testing-Skin-Biopsy/2471222/Generalized pustular psoriasis (GPP) treatment should not be delayed while waiting for a tuberculosis screening, according to Mark Lebwohl, MD. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Lebwohl recommended initiating spesolimab therapy immediately
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como
- Bimekizumab Shown Safe at 3 Years for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/bimekizumab-shown-safe-at-3-years-for-moderate-to-severe-plaque-psoriasis/2462216/In a poster presented at Maui Derm, 2024, results from a long-term pooled analysis from five phase-3/3b trials indicate that bimekizumab (BKZ) is safe and well-tolerated at the 3-year mark in patients with moderate-to-s
- Amorepacific Receives the CES Innovation Award for 'Lipcure Beam'https://practicaldermatology.com/news/amorepacific-receives-the-ces-innovation-award-for-lipcure-beam/2462138/Amorepacific's 'Lipcure Beam' technology received the Consumer Electronics Show 2024 (CES 2024) Innovation Award, marking the company's fifth consecutive win at the tech event. The 'Lipcure Beam' combines lip diagnosis, care, and makeup capabilities in one unit.
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Eczema Breakthrough: S. aureus Evolve to a Variant with a Mutation in a Specific Gene to Grow Fasterhttps://practicaldermatology.com/news/eczema-breakthrough-s-aureus-evolve-to-a-variant-with-a-mutation-in-a-specific-gene-to-grow-faster/2461659/New research shows how Staphylococcus aureus gains mutations that allow it to colonize eczema patches. In people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin. This study marks the first t